S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:VERU

Veru (VERU) Stock Forecast, Price & News

$13.38
-0.91 (-6.37%)
(As of 05/20/2022 04:00 PM ET)
Add
Compare
Today's Range
$12.66
$14.21
50-Day Range
$4.35
$15.60
52-Week Range
$4.34
$17.50
Volume
11.55 million shs
Average Volume
24.79 million shs
Market Capitalization
$1.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.57
30 days | 90 days | 365 days | Advanced Chart
Receive VERU News and Ratings via Email

Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter.

Veru logo

About Veru

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Headlines

Veru (NASDAQ:VERU) Shares Gap Up After Analyst Upgrade
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Personal Products
Sector
Medical
Current Symbol
NASDAQ:VERU
CUSIP
31446210
Employees
252
Year Founded
N/A

Sales & Book Value

Annual Sales
$61.26 million
Book Value
$1.70 per share

Profitability

Net Income
$7.39 million
Pretax Margin
-50.75%

Debt

Price-To-Earnings

Miscellaneous

Free Float
61,577,000
Market Cap
$1.07 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/12/2022
Today
5/21/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
9/30/2022

MarketRank

Overall MarketRank

2.29 out of 5 stars

Medical Sector

277th out of 1,420 stocks

Pharmaceutical Preparations Industry

103rd out of 679 stocks

Analyst Opinion: 4.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -













Veru (NASDAQ:VERU) Frequently Asked Questions

Is Veru a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veru in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Veru stock.
View analyst ratings for Veru
or view top-rated stocks.

Are investors shorting Veru?

Veru saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 14,430,000 shares, an increase of 31.9% from the April 15th total of 10,940,000 shares. Based on an average daily trading volume, of 17,320,000 shares, the short-interest ratio is presently 0.8 days. Approximately 22.4% of the shares of the stock are short sold.
View Veru's Short Interest
.

When is Veru's next earnings date?

Veru is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Veru
.

How were Veru's earnings last quarter?

Veru Inc. (NASDAQ:VERU) posted its quarterly earnings data on Thursday, May, 12th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.02. Veru had a negative trailing twelve-month return on equity of 18.64% and a negative net margin of 45.56%. During the same period in the previous year, the business posted ($0.04) earnings per share.
View Veru's earnings history
.

What price target have analysts set for VERU?

5 Wall Street analysts have issued 1 year price targets for Veru's stock. Their forecasts range from $24.00 to $55.00. On average, they expect Veru's stock price to reach $35.40 in the next year. This suggests a possible upside of 164.6% from the stock's current price.
View analysts' price targets for Veru
or view top-rated stocks among Wall Street analysts.

Who are Veru's key executives?
Veru's management team includes the following people:
  • Dr. Mitchell S. Steiner F.A.C.S, F.A.C.S., M.D., Chairman, Pres & CEO (Age 61, Pay $1.43M)
  • Dr. Harry Fisch F.A.C.S., M.D., Vice Chairman & Chief Corp. Officer (Age 63, Pay $648.12k)
  • Ms. Michele Greco, CFO & Chief Admin. Officer (Age 63, Pay $659.62k)
  • Dr. K. Gary Barnette Ph.D., Chief Scientific Officer (Age 54, Pay $636.7k)
  • Mr. Samuel Fisch, Exec. Director of Investor Relations & Corp. Communications
  • Mr. Michael J. Purvis, Exec. VP, Gen. Counsel & Corp. Strategy and Sec.
  • Mr. Kevin J. Gilbert CPA, J.D., Exec. VP of Corp. Devel.
  • Dr. Robert H. Getzenberg Ph.D., Exec. VP for Medical Affairs
  • Dr. Domingo Rodriguez, Exec. VP of Clinical Operations (Age 60)
  • Mr. Gary Bird Ph.D., Sr. VP of Quality Oversight
What other stocks do shareholders of Veru own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Kadmon (KDMN), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Matinas BioPharma (MTNB), OrganiGram (OGI), Vaxart (VXRT), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

What is Veru's stock symbol?

Veru trades on the NASDAQ under the ticker symbol "VERU."

Who are Veru's major shareholders?

Veru's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.14%), Vanguard Group Inc. (3.93%), State Street Corp (1.45%), Northern Trust Corp (0.73%), Blair William & Co. IL (0.41%) and Royal Bank of Canada (0.32%). Company insiders that own Veru stock include Harry Fisch, K Gary Barnette, Lucy Lu, Michele Greco and Mitchell Shuster Steiner.
View institutional ownership trends for Veru
.

Which institutional investors are selling Veru stock?

VERU stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Jane Street Group LLC, UBS Group AG, Northern Trust Corp, JPMorgan Chase & Co., GSA Capital Partners LLP, Cutler Group LP, and MetLife Investment Management LLC.
View insider buying and selling activity for Veru
or view top insider-selling stocks.

Which institutional investors are buying Veru stock?

VERU stock was acquired by a variety of institutional investors in the last quarter, including Royal Bank of Canada, Vanguard Group Inc., Graham Capital Management L.P., State Street Corp, Prudential Financial Inc., Renaissance Technologies LLC, Belvedere Trading LLC, and Walleye Capital LLC. Company insiders that have bought Veru stock in the last two years include Harry Fisch, Lucy Lu, and Michele Greco.
View insider buying and selling activity for Veru
or or view top insider-buying stocks.

How do I buy shares of Veru?

Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Veru's stock price today?

One share of VERU stock can currently be purchased for approximately $13.38.

How much money does Veru make?

Veru has a market capitalization of $1.07 billion and generates $61.26 million in revenue each year. The company earns $7.39 million in net income (profit) each year or ($0.340010) on an earnings per share basis.

How many employees does Veru have?

Veru employs 252 workers across the globe.

What is Veru's official website?

The official website for Veru is www.veruhealthcare.com.

How can I contact Veru?

Veru's mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The company can be reached via phone at (305) 509-6897, via email at [email protected]a.com, or via fax at 312-595-9122.

This page was last updated on 5/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.